Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IFNA1
REST API REST API
Homo sapiens
IFNA1 is differentially expressed in 166 experiments: 89 organism parts: bone marrow, prostate, ... (87 more);, 127 disease states: normal, acute promyelocytic leukemia, ... (125 more);, 41 cell types 124 cell lines 12 compound treatments and 62 other conditions.
Synonyms IFN-ALPHA, IFNA@, IFNA13, IFN-alphaD, IFL, IFN
Orthologs Gm13280 (Mus musculus)   Ifnab (Mus musculus)   ENSBTAG00000025928 (Bos taurus)   F1MRU7_BOVIN (Bos taurus)   Gm12597 (Mus musculus)   Ifna12 (Mus musculus)   ENSBTAG00000022787 (Bos taurus)   Ifna9 (Mus musculus)   Ifna6 (Mus musculus)   E1B7E8_BOVIN (Bos taurus)   Ifna5 (Mus musculus)   Ifna1 (Mus musculus)   Ifna7 (Mus musculus)   Ifna13 (Mus musculus)   Ifna14 (Mus musculus)   F1LU40_RAT (Rattus norvegicus)   F1LU43_RAT (Rattus norvegicus)   Ifna2 (Mus musculus)   RGD1560539 (Rattus norvegicus)   Ifna2 (Rattus norvegicus)   Ifna1 (Rattus norvegicus)   Ifna4 (Mus musculus)   Ifna11 (Mus musculus)   LOC100365568 (Rattus norvegicus)   F1LYF0_RAT (Rattus norvegicus)   RGD1564517 (Rattus norvegicus)   LOC690891 (Rattus norvegicus)   Ifna11 (Rattus norvegicus)   F1LVV9_RAT (Rattus norvegicus)   RGD1565623 (Rattus norvegicus)   F1LU02_RAT (Rattus norvegicus)   RGD1565911 (Rattus norvegicus)   ENSBTAG00000046427 (Bos taurus)   IFNAC (Bos taurus)   XM_849076.1 (Canis familiaris)   ENSCAFG00000023723 (Canis familiaris)   IFNA1_CANFA (Canis familiaris)   IFNA1_CANFA (Canis familiaris)   ENSCAFG00000024020 (Canis familiaris)   IFNA1_CANFA (Canis familiaris)   ENSCAFG00000024220 (Canis familiaris)   IFNA1_CANFA (Canis familiaris)   IFNA1_CANFA (Canis familiaris)   NP_001006648.1 (Canis familiaris)   ENSCAFG00000001657 (Canis familiaris)   IFNA1_CANFA (Canis familiaris)   ENSCAFG00000001668 (Canis familiaris)   IFNA1_CANFA (Canis familiaris)   IFNA1_CANFA (Canis familiaris)   F1MVJ9_BOVIN (Bos taurus)   F1MLP8_BOVIN (Bos taurus)   F1MRX9_BOVIN (Bos taurus)   IFNA1_CANFA (Canis familiaris)   IFNAA (Bos taurus)   (Compare orthologs)
Gene Ontology Term cytokine-mediated signaling pathway, extracellular space, innate immune response, extracellular region, blood coagulation, cytokine activity, defense response, cytokine receptor binding, regulation of type I interferon-mediated signaling pathway, interferon-alpha/beta receptor binding, response to virus, type I interferon-mediated signaling pathway
InterPro Term Interferon_alpha/beta/delta
UniProt Accession P01562
Search EB-eye ENSG00000197919
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MTAB-24, E-MTAB-25, E-GEOD-6919, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-22152, E-GEOD-22639, E-GEOD-19639, E-GEOD-2450, ... (21 experiments)

Factor Value U/D Experiments
BT474
2
 E-MEXP-440, E-MTAB-62
HCC1395
1
 E-MTAB-37
LS174T
1
 E-MTAB-37
C7H2-S27
1
 E-GEOD-22152
GM07348
1
 E-TABM-321
JAR
1
 E-MTAB-37
118 more value(s).


Cell type

studied in E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-MTAB-24, E-MTAB-25, ... (21 experiments)

Factor Value U/D Experiments
1
2
 E-TABM-145, E-TABM-130
dendritic cell-derived intermediate cell
1
 E-MEXP-2019
CD71+ early erythroid
1
 E-AFMX-5
bronchial epithelial
1
 E-AFMX-5
721 B lymphoblast
2
1
 E-AFMX-5
leydig cell
1
 E-MTAB-25
35 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-8514, E-TABM-15, ... (34 experiments)

Factor Value U/D Experiments
control
2
 E-GEOD-20602, E-GEOD-21912
plasma-cell leukemia
1
 E-MTAB-62
chronic myelogenous leukemia, indolent
1
 E-MTAB-62
Huntington's disease
1
 E-GEOD-1751
urinary tract infection
1
 E-MTAB-62
adenocarcinoma
1
 E-MEXP-1331
121 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-3284, E-GEOD-412, E-GEOD-5824, E-MEXP-2241, ... (8 experiments)

Factor Value U/D Experiments
none
2
 E-GEOD-412, E-GEOD-5824
no estradiol
1
 E-GEOD-20081
bacterial endotoxin
1
1
 E-GEOD-3284
ethanol
4
1
 E-MEXP-2241
glutamine
1
1
 E-MEXP-941
trichostatin A
1
 E-MEXP-1269
6 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
 E-GEOD-19519
tunicamycin
1
1
 E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-18995 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-6236, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-563

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-321, E-TABM-601 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-MEXP-1648, E-TABM-15, ... (28 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-3697, E-GEOD-3485

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-20677, E-GEOD-22368, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Tumor size
studied in E-GEOD-4922

Processing time: 0.458 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM